The global wound care sealants market is expected to experience a lucrative growth on account of increasing number of surgeries all over the world. Advancement in wound care products which include hydrocolloids, fibrin, collagen, hydrogels, rising awareness among the population about the new technological advancements coupled with the increasing disposable income is expected to fuel industry growth over the forecast period. The innovations in the field of adherence products which include fibrin and collagen and bio-active wound sealant are projected to stimulate the market demand on account of the fact that they are expected to be very suitable to reduce post-surgery complexities and open wound associated incidents of fluid accumulation, swelling, and hematomas.
Increasing funds and grants by governments for research & development which results in the innovations of novel products will propel industry expansion over the forecast period. The rising occurrences of infections acquired by the hospitals are stimulating the demand for sterile and better product technologies.
Asia Pacific market is anticipated to provide a broad range of opportunities for expansion of the wound care sealants market in this region owing to technological development in India, Australia, China, and South Korea. However, high costs of advanced wound healing products are expected to hinder industry growth over the forecast period.
Wound repair or wound heal is the physiological process by which the body heals skin and organ tissue post-injury. Hemostasis is the first step that starts instantaneously post-injury subsequently fibrin clot formation takes place. The segmentation by product types include glues, absorbable hemostats, sealants, and adhesion prevention products. Solid and liquid sealants are being developed for various procedures and are expected to be effective by having adhesive properties. Biocompatible and biodegradable sealants are preferred during surgical procedures.
Segmentation, by biomolecule base, includes collagen fibrin based and synthetic adhesive and glues. Fibrin based are the only agents which have been approved as a sealant, adhesive by the FDA and hemostat, and with innovations of commercially available fibrin sealants are expected to augment the wound care sealants market demand over the upcoming years.
By product usage in wound care dressings, products are subdivided into collagen, foam dressings, alginates, films, hydrogels, hydrocolloids, and super absorbers. On account of excessive usage of foam based dressings and sealants as primary or secondary wound care on various types of a wound from low to moderate exudates will fuel its demand.
Ongoing advancements of wound healing are expected to result in the rapid expansion of tissue sealants, platelet gels, and use of growth factors. Tissue sealants act as a substitute for the closure of non-surgical and surgical wounds. The use of the product is to reduce the excess loss of blood during the injuries. Biomaterials are reported as wound sealant which includes mussel-adhesive proteins, dendrimers, in-situ forming hydrogels, and keratin. Platelet gels have clot forming property along with the release of growth factors. Dermal ulcers treatment is done by the usage of recombinant platelet-derived from growth factor.
The presence of advanced technologies and FDA approval for hemostatic and sealant agents are the factors contributing to its largest share. Asia Pacific market is anticipated to grow at a fast pace owing to the presence of a large untapped share of the market and growing awareness about wound care and wound management.
The major market participants include 3M Company Inc., C.R. Bard, Smith and Nephew, Baxter International, Inc., Coloplast A/S, Derma Sciences, Inc., Hollister, Inc., Molnlycke Health Care AB and Ethicon, ConvaTec Healthcare B S.A.R.L., Inc. (a subsidiary of Johnson and Johnson).
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
"The quality of research they have done for us has been excellent."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.